Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699326 | 0.85 | KMT2A (0.37) | LMNAMEN1KMT2ARAB9AMAPT | |
| SCHEMBL20703425 | 0.84 | MEN1 (0.37) | LMNAMEN1KMT2ARAB9AMAPT | |
| SCHEMBL24608742 | 0.84 | ALDH1A1 (0.41) | LMNAOPRL1KMT2AALDH1A1KDM4E | |
| SCHEMBL31115330 | 0.82 | LMNA (0.40) | LMNAMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL14894428 | 0.78 | OPRL1 (0.45) | OPRL1 | |
| SCHEMBL14894433 | 0.77 | SLC6A4 (0.44) | LMNAOPRM1 | |
| SCHEMBL2130769 | 0.77 | OPRL1 (0.44) | LMNAOPRL1MEN1KMT2AHDAC1 | |
| SCHEMBL237739 | 0.74 | OPRL1 (0.38) | LMNAOPRL1RAB9AMAPTHDAC1 | |
| SCHEMBL1141468 | 0.74 | LMNA (0.53) | LMNAOPRL1MEN1KMT2AMAPK1 | |
| SCHEMBL237773 | 0.74 | LMNA (0.49) | LMNAOPRL1HDAC1ALDH1A1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3694502-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074747-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-9221838-B2 | Inhibitors of AKT activity | ALMAC DISCOVERY LIMITED (IE) | 2015-12-29 | — | — | US | disclosed |
| EP-2516435-B1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-2516435-A1 | INHIBITORS OF AKT ACTIVITY | Almac Discovery Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077098-A9 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | LMNA 3443/4885OPRL1 4483/4885MEN1 1436/4885 |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | LMNA 4584/4885OPRL1 2475/4885MEN1 2348/4885 |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | LMNA 4734/4885OPRL1 2153/4885MEN1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.